Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises - 2Misremembering might actually be a sign your memory is working optimally
- 3New Gaza militia declares war on Hamas: 'Your dirty shoes are more honorable'
- 4The Best Web-based Courses for Expertise Improvement
- 5SUVs Known for Their Looks As opposed to Their Capacity
- Moon-bound Artemis II astronauts enjoy a relaxed day in space
- Figure out How to Remain Informed about the Most recent Open Record Extra Offers
- The most effective method to Boost Benefits in Gold Speculation: Master Techniques and Tips
- The 10 Most Significant Games in History
- IDF destroys Hamas shaft in northern Gaza with loaded 'ready to fire' rocket aimed at Sderot
- Step by step instructions to Appropriately Keep up with Your Sunlight powered chargers for Most extreme Productivity
- Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
- Woman leaves bachelorette trip after trusting her gut about sketchy men partying it up with friends
- The wolf supermoon will kick off 2026 with a celestial bang. Here's when and how to see it.
